Preclinical Pipeline
| Program | Modality | Indication | Discovery | Lead | Preclinical |
|---|---|---|---|---|---|
| TSRF-786C | Anti-CD155 Naked IgG4 mAb | Solid Tumors / Advanced Malignancies |
✓
|
✓
|
✓
|
| TSRF-ADC | Anti-CD155 ADC | Solid Tumors / Refractory Cancers |
✓
|
||
| TSRF-Nucleic Acid Conjugate | Anti-CD155 Nucleic Acid Conjugate | Solid Tumors/Refractory Cancers |
✓
|
||
| TSRF-CNS | Anti-CD155 × Anti-TfR Bispecific | CNS Tumors |
✓
|
||
| TSRF-IO | Anti-CD155 T-Cell Engager | Blood and Solid Tumors |
✓
|
||
| TSRF CAR-NK and CAR-T | Anti-CD155 Cell Therapy | Blood and Solid Tumors |
✓
|
Tasrif Pharmaceutical is a preclinical stage company.
No products are in clinical use and none of the products are FDA approved.
